75 results about "Cell response" patented technology

The invention discloses an alpha nuclide drug in-vitro cellular response prediction method and system based on multi-module mathematical modeling and a medium, and the method comprises the steps: constructing a basic parameter input module, a pharmacokinetic prediction module, a cell absorbed dose calculation module and a biological effect prediction module which are connected in sequence; a three-compartment dynamical model and a micro-dose learning point kernel convolution and DNA damage repair dynamical model are integrated, and full-chain and quantitative simulation from drug distribution, microscopic energy deposition to cell survival is achieved. The method overcomes the defects that an existing empirical model cannot accurately reflect the high LET characteristic of alpha particles, neglects the bystander effect and repair dynamics and the like, and the prediction precision is remarkably improved. According to the method, the curative effects of different drugs, cell lines and dosage schemes can be quickly simulated on a computer, the research and development cost and period are greatly reduced, and an efficient theoretical tool is provided for new drug screening and dosage optimization.

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

In order to provide a new agent for hair pigmentation treatment in subjects, the present invention suggests an active agent for use in the treatment of hair pigmentation, wherein the active agent activates, enhances, inactivates, blocks or dampens the cellular response of the taste receptor TAS2R50 or interferes with the expression of said receptor. Furthermore, the present invention is directed to the use of said active agent as a medicament, a cosmetic or a food supplement in therapeutical or non-therapeutical treatment of hair pigmentation. In addition, the invention is directed to a corresponding cosmetic or medical hair pigmentation regulating or modulating composition or food supplement.

The invention provides a cell reaction bag with a double-gas-path ventilation device, the cell reaction bag comprises a reaction bag body, a ventilation device and a stirring device, the ventilation device comprises a ventilation disc, the ventilation disc is provided with a first hole group and a second hole group, and the ventilation disc is internally provided with a first channel and a second channel which are respectively communicated with the first hole group and the second hole group; the bottom of the ventilation disc is provided with a first air inlet and a second air inlet which are communicated with the first channel and the second channel respectively. According to the ventilation device disclosed by the invention, two groups of holes with different sizes and corresponding channels are arranged, so that double-gas-path ventilation is formed, different gases can be respectively introduced, large bubbles are generated on the outer side of the ventilation disc, and micro bubbles are generated on the inner side of the ventilation disc; the gas dissolving efficiency is improved, uniform gas distribution is ensured, and uniform growth of cells is facilitated; different requirements on gases such as oxygen and carbon dioxide in the cell culture process can be accurately controlled, and a more suitable gas environment is provided for cell growth.

Disclosed herein are branched chain amino acid transaminase 1 (BCAT1) inhibitors and uses thereof. More specifically, disclosed are BCAT1 inhibitors that limit amino acid metabolism essential for CD4+ T-cell responses and their use in preventing, improving, or treating inflammatory disease or autoimmune disease. By identifying that BCAT1 acts as a major regulator in the inflammatory response of CD4+ T-cells, it is possible to regulate the inflammatory response by CD4+ T cells secreting interleukin-17 (IL-17), which is a major immune cell of autoimmune diseases, by utilizing a BCAT1 inhibitor.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and / or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.

The invention relates to the technical field of active ingredient extraction, and particularly provides an extraction method for classifying and screening active ingredients, raw materials are subjected to low-temperature freeze-drying pretreatment by adopting supercritical CO2, and treatment is performed for 4-6 hours under the conditions of minus 40-minus 20 DEG C and 8-12 MPa, so that the active ingredients are reserved to the greatest extent; through gradient ultrasonic-assisted extraction of ultrapure water, a 50% ethanol solution and a 95% ethanol solution, step-by-step separation of water-soluble, alcohol-soluble and fat-soluble components is realized; carrying out multi-dimensional purification by using a composite chromatographic column containing a 0.2 mu m ceramic membrane layer, a macroporous adsorption resin layer and a sephadex layer; a two-channel biosensor array is adopted to synchronously detect a cell response signal and a molecule binding signal, and components with the activity intensity reaching 80% or above are screened; and finally, carrying out vacuum rotary evaporation concentration and spray drying to obtain a finished product, and completing system purity verification through a high performance liquid chromatography-mass spectrometry technology to form a complete quality control system.

The invention discloses a laminar flow micro-fluidic chip and method for detecting spatial heterogeneous drug distribution influence, the chip comprises a fluid layer and a control layer, the fluid layer comprises a first main inlet and a second main inlet, the fluid layer further comprises a plurality of independent cell culture chambers of an array, the control layer comprises a control valve inlet and a pneumatic valve array, and the control valve inlet is communicated with the pneumatic valve array. The independent cell culture chamber is composed of a concave cavity, the independent cell culture chamber is provided with two semicircular enclosures, a first channel inlet and a second channel inlet are formed in the independent cell culture chamber, and peristaltic pump subunits are arranged on the first channel inlet and the second channel inlet. Laminar flow control is achieved by integrating the pneumatic valve and the peristaltic pump, and chemical gradient generation and cell response monitoring of micron-sized spatial resolution are achieved through automatic control.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

A method of preparing cells for therapeutic use is provided in which a population of progenitor cells is cultured under cell culture conditions that promote progenitor cell differentiation, the cell culture conditions comprising the presence of G-CSF, GM-CSF, IL-3, and TNF; to produce a population of granulocytic cells. The produced granulocytic cells are useful in methods of treatment, including the treatment of cancer and infections, and the modulation of inflammatory cell responses.

Systems and methods for identifying cellular responses to candidate drugs, including treatment cycling, are described. These systems and methods utilize rapid response readout in combination with gentle removal and / or exchange of the analyte fluid. The systems and methods can be used, for example, in T-cell epitope mapping, T-cell diagnostics, and other cell-based high-throughput screening methods.

A method for preparing cells for therapeutic use is provided, comprising culturing a population of progenitor cells under cell culture conditions that promote progenitor cell differentiation, including the presence of G-CSF, GM-CSF, IL-3, and TNF, to generate a population of granulocyte-producing cells. The generated granulocyte-producing cells may be useful in therapeutic methods, including the treatment of cancer and infections, and may also be useful in modulating inflammatory cell responses.

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

The invention relates to a cell culture reactor in a full temperature control mode, and relates to the technical field of cell culture reaction equipment. The cell culture reactor in the full temperature control mode comprises a shell, a heating cavity is formed in the shell, a bottom plate and a bottom heater are arranged in the heating cavity, the bottom plate is used for placing a cell reaction bag, the bottom heater is used for heating the bottom plate, a cavity heating mechanism is further arranged in the shell, and the cavity heating mechanism is used for heating the cell reaction bag. And the cavity heating mechanism comprises a heating fan, and the heating fan is used for heating gas in the heating cavity. The device has the effect of ensuring the heating uniformity of the cell reaction bag.

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

To provide vaccines and methods.SOLUTION: Described herein are methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response and associated T-cell responses to a pathogen, and nucleic acid sequences encoding such polypeptides. Also described are methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide or a nucleic acid encoding the optimized pathogen polypeptide. Further described are nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses).SELECTED DRAWING: None

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

A mesoscopic unit cell analysis method for bending mechanical behaviors of a three-dimensional braided composite material relates to the field of mechanical property analysis, and comprises the following steps: obtaining mesoscopic characteristics and geometric parameters of a material, and establishing a mesoscopic unit cell finite element model with in-plane periodicity and thickness consistent with that of a sample; the method comprises the following steps: enabling a four-point bending sample to be equivalent to an in-plane periodically distributed thin plate structure, establishing association between macroscopic thin plate deformation and mesoscopic unit cell deformation based on a homogenization method, and deducing periodic boundary conditions; applying a boundary condition on the mesoscopic unit cell finite element model to simulate a mesoscopic mechanical response under a four-point bending load; and macroscopic bending performance parameters are obtained through microcosmic stress field homogenization treatment. According to the method, the in-plane periodic mesoscopic unit cell finite element model with the thickness consistent with that of the sample is established, the periodic boundary condition and the homogenization method are combined, macroscopic thin plate deformation and unit cell mesoscopic response are associated, and the applicability problem caused by non-periodicity of a traditional unit cell model in the thickness direction under the bending load is solved.

Cell analysis systems and instruments provide end users with time history graphics and imaging data of individual cell responses as caused by perturbations in the cell microenvironment and monitored by ChemFET sensors. The imaging data of the cellular response may be presented as an electron microscope image that is either an image taken from a sensor covering a cell footprint at a defined sampling interval of the cellular response or an image of the cellular response for a sensor detecting cellular effluents. Electron microscope imaging may be compared to optical imaging to provide information about additional dimensions of cellular analysis. For example, optical imaging using a known set of markers to compare immunocytochemical studies provides functional and phenotypic characteristics of data obtained for each cell analyzed using a ChemFET-based cellular analysis system.

The invention relates to an A beta antigen compound based on an AP205 or Lus nanoparticle carrier, a vaccine containing the A beta antigen compound and a preparation method and application of the A beta antigen compound. According to the A beta antigen compound disclosed by the invention, A beta antigen epitope peptide is efficiently loaded on an AP205 / Lus nanoparticle carrier by utilizing a specific SpyCatcher-SpyTag biological coupling system and is self-assembled to form a 180 / 60 polymer spherical structure, so that the A beta antigen epitope peptide is displayed on the surface of the spherical structure to form an ordered and repeated antigen array; therefore, an organism can be stimulated to generate a specific immune response aiming at the A beta protein to the greatest extent, and the immunogenicity is relatively high; the vaccine based on the A beta antigen compound can induce a body to generate a high-titer A beta antibody, and does not induce to generate a T cell reaction aiming at A beta, so that the vaccine has relatively high safety.

The invention relates to an A beta antigen compound based on ferritin nanoparticles, a vaccine containing the A beta antigen compound as well as a preparation method and application of the A beta antigen compound. According to the A beta antigen compound disclosed by the invention, A beta antigen epitope peptide is efficiently loaded on a ferritin nanoparticle carrier by utilizing a specific SpyCatcher-SpyTag biological coupling system and is self-assembled to form a 24-polymer spherical structure, so that the A beta antigen epitope peptide is displayed on the surface of the spherical structure to form an ordered and repeated antigen array; therefore, an organism can be stimulated to generate a specific immune response aiming at the A beta protein to the greatest extent, and the immunogenicity is relatively high; the vaccine based on the A beta antigen compound can induce a body to generate a high-titer A beta antibody, and does not induce to generate a T cell reaction aiming at A beta, so that the vaccine has relatively high safety.

The present invention provides compounds and compositions for inhibiting complement-mediated damage to cells, tissues, or organs. [Solution] The present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. Furthermore, it provides methods for using cell-reactive compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. Furthermore, it provides methods for using long-acting compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides targeted compstatin analogs and compositions comprising targeted compstatin analogs.

Reprogramming adult or somatic cells into induced pluripotent stem cells (iPSCs) is widely recognized as an inefficient process, with success rates typically below 1%, and is characterized by significant heterogeneity. Numerous strategies have been explored to enhance reprogramming efficiency, including chemical, biochemical, and biophysical manipulations. However, achieving high-efficiency iPSC production and generating cell lines with consistent molecular properties that enable reliable dow nstream differentiation into therapeutically or diagnostically relevant cell ty pes remain poorly understood. The compositions and methods described herein address these challenges by significantly improving the efficiency of iPSC reprogramming. Moreover, the resulting iPSCs exhibit molecular characteristics that enhance cellular responses and differentiation capabilities, allowing for optimization in specific therapeutic and diagnostic applications.

The invention relates to a human body self-adaptive micro-current stimulation method and system.The electrode points of the human body self-adaptive micro-current stimulation system are arranged in an array mode on a two-dimensional structure, the corresponding electrode points are controlled to output multi-frequency micro-current detection signals to all detected areas according to a preset point scanning mode, and cell response data are collected; performing feature extraction on the cell response data, and constructing a response state model of the detected area; acquiring a macroscopic model library and a microscopic model library, performing primary comparison on the response state model and the macroscopic model library, and determining personalized stimulation parameters according to a primary comparison result; performing secondary comparison on the response state model and the microscopic model library, and determining an optimal stimulation electrode combination according to a secondary comparison result; and generating an optimal treatment scheme according to the optimal stimulation electrode combination and the personalized stimulation parameters, and performing electrical stimulation on a target stimulation part of the treatment object through an electrode stimulation module.

This invention provides a tumor peptide vaccine for treating breast cancer and a method for preparing the same, wherein the tumor peptide vaccine comprises: a peptide mixture containing 8 CD8+ molecules. + T cell epitopes peptide fragments and 3 CD4+ + polypeptide fragments of T cell epitopes; the eight CD8... + The amino acid sequences of the polypeptide fragments of T cell epitopes are shown in SEQ ID NO: 1-8, and the three CD4 lines... + The amino acid sequences of the polypeptide fragments of T cell epitopes are shown in SEQ ID NO: 9-11; all of the polypeptide fragments are synthesized from mutant polypeptide sequences of the tumor-associated gene SWAP70; the present invention has the beneficial effect of effectively promoting the generation of T cell responses in the body and is applicable to the field of tumor immunology.

The present disclosure provides an element for transcription initiation derived from a porcine Hsp40 gene and use thereof. The promoter element of the present disclosure is helpful for revealing the structure of the porcine HSP40 / DNJB6 gene core promoter and the regulation mechanism thereof in cell response, and has important significance for understanding the structure and function of the promoter for deeply knowing the molecular regulation mechanism of pigs, and also provides a new perspective and tool for gene expression research in the related fields.

The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.

The application discloses a kind of based on knowledge graph's cancer cell line drug response prediction large language model construction method.The method fuses the structured information of biological knowledge graph and the semantic reasoning ability of large language model, realizes the multi-level modeling and explainable prediction of drug-cell reaction mechanism.The method comprises the following steps: first, integrate multi-source data to construct multi-modal dataset;Second, establish the drug response knowledge graph containing drug, gene and other entities;Then, fine-tune the model using LoRA technology and inject graph embedding, realize cross-modal alignment;Further, dynamic knowledge retrieval and enhancement are carried out using RAG technology;Finally, output drug sensitivity prediction and natural language explanation.The application significantly improves the prediction accuracy and explainability, and can reveal the key gene pathway, providing an efficient intelligent tool for precision cancer treatment.

The present disclosure provides antibodies specific for glypican-3 (GPC3). Nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are useful in various diagnostic, and monitoring applications, which are also provided.